Ó£ÌÒÊÓƵ

Cancer vaccine cuts melanoma risk nearly 50% in breakthrough study

A new injectable therapy is showing positive results in reducing melanoma throughout a five-year period. The personalized mRNA cancer therapy, combined with the cancer immunotherapy drug KEYTRUDA, is a collaboration between Merck and Moderna.

A new injectable therapy is showing positive results in reducing melanoma throughout a five-year period. The personalized mRNA cancer therapy, combined with the cancer immunotherapy drug KEYTRUDA, is a collaboration between Merck and Moderna.